| Literature DB >> 35616397 |
Juanjuan Su1,2,3,4, Haimeng Li1,2,3,4, Jingyang Hu1,2,3,4, Danni Wang1,2,3,4, Fengchao Zhang1,2,3,4, Zheng Fu1,2,3,4, Feng Han1,2,3,4.
Abstract
Antimicrobial peptides (AMPs) are currently recognized as potentially promising antibiotic substitutes. Fish are an important seawater/freshwater medicinal biological resource, and the antimicrobial peptides and proteins that are key components of their innate immune systems are potential candidates for the development of novel antibacterial agents. The rainbow trout Oncorhynchus mykiss chemokine CK11 (omCK11), classified in the C-C motif chemokine ligand 27/28 (CCL27/28) family, is the only CC-type chemokine reported to play a direct antibacterial role in the immune response; however, its antibacterial domain remains unknown. In this study, we analyzed the structure-activity relationship of omCK11 and identified the antibacterial C-terminal domain. Additionally, we performed structure-function analyses of CCL27/28 proteins from different, representative freshwater and seawater fishes, revealing their shared C-terminal antibacterial domains. Surprisingly, a synthesized cationic peptide (named lcCCL28-25), derived from the large yellow croaker Larimichthys crocea CCL28, exhibited broad-spectrum and the most acceptable bactericidal activity, as well as antibiofilm activity and negligible hemolytic and cytotoxic activity in vitro. Additionally, lcCCL28-25 conferred a protective effect in the thighs of neutropenic mice infected with Staphylococcus aureus. SYTOX green fluorescence and electron microscopy experiments revealed that lcCCL28-25 was capable of rapidly destroying the integrity and permeability of the bacterial cell membrane. Overall, this study aided in the advancement of antibacterial CC-type chemokine research and also suggested a new strategy for exploring novel AMPs. Additionally, the efficacy of lcCCL28-25 in in vivo antibacterial activity in a mammalian model revealed that this compound could be a promising agent for the development of peptide-based antibacterial therapeutics. IMPORTANCE The primary function of chemokines has been described as recruiting and activating leukocytes to participate in the immune response. Some chemokines are also broad-spectrum antibacterial proteins in mammals. The Oncorhynchus mykiss chemokine CK11 (omCK11) is the first reported and currently the only CC-type antibacterial chemokine. The present study identified the antibacterial domain of omCK11. Structure-function analysis of various fish CCL27/28 proteins identified a novel antibacterial peptide (lcCCL28-25) from Larimichthys crocea CCL28 that exhibited broad-spectrum and the most acceptable bactericidal activity in vitro, as well as a protective effect in a Staphylococcus aureus infection mouse model. The antibacterial mechanisms included membrane disruption and permeation. This study advanced the field of antibacterial chemokine research in fish and also suggested a new strategy for exploring novel AMPs. The novel peptide lcCCL28-25 may prove to be an effective antibacterial agent.Entities:
Keywords: Staphylococcus aureus; antibacterial activity; antimicrobial peptide; bacterial resistance; negligible toxicity
Mesh:
Substances:
Year: 2022 PMID: 35616397 PMCID: PMC9241943 DOI: 10.1128/spectrum.02515-21
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
FIG 1Structural features of O. mykiss CK11 (omCK11). (A) Three-dimensional model of omCK11. Structures in green, yellow, and red represent the N-terminal random coil region (Gly1–Val22), the middle 3-stranded antiparallel β-sheet region (Glu23–Ala50), and the C-terminal α-helix region (Asp51–Arg80). (B) Electrostatic potential surface maps of omCK11 in which areas with positive charges are shown in blue and negative charges in red. (C) Helical wheel plot of the omCK11-31 peptide. The yellow background points to the hydrophobic residues, F, L, M, I and V, the blue to the positively charged hydrophilic residues, K and R, and the red to the negatively charged hydrophilic residue (D). The light green represents the proline (P), the pink represents the asparagine (N) and glutamine (Q), and the gray represents glycine (G) and alanine (A). (D) CD spectroscopy of omCK11-31 (200 μg/mL) in water and 50% TFE solution.
FIG 2Protein sequence alignment, electrostatic potential surface diagram, and helical wheel plot analysis. (A) Protein sequence alignment of O. mykiss CK11 (omCK11; GenBank accession no. CDQ77591.1), O. mykiss CCL28-like (omCCL28-like; GenBank accession no. CDQ62061.1), D. rerio CCL27b (drCCL27b; GenBank accession no. NP_001121740.1), L. crocea CCL28 (lcCCL28; GenBank accession no. XP_010731843.1), S. maximus CCL27b (smCCL27b; GenBank accession no. XP_035496366.1), T. rubripes CCL28 (trCCL28; GenBank accession no. NP_001266955.1), and C. harengus CCL27a (chCCL27a; GenBank accession no. XP_012669911.2). Red background represents the same amino acid residues, and blue frames indicate amino acid residues with identities of >70%. (B, E, H, K, N, and Q) Electrostatic potential surface diagrams of proteins. Areas with positive charges are indicated in blue, and negative charges in red. (C, F, I, L, O, and R) Helical wheel plots of the C-terminal segments. The hydrophobic residues, F, L, M, I, V, Y, and W are in a yellow background, the positively charged hydrophilic residues, K and R, in blue, and the negatively charged hydrophilic residues, D and E in red. Light green represents proline (P), light blue represents histidine (H), pink represents asparagine (N) and glutamine (Q), purple represents serine (S) and threonine (T), and gray represents glycine (G) and alanine (A). (D, G, J, M, P, and S) CD spectroscopy of the C-terminal peptides (200 μg/mL) in water and 50% TFE solution. (C, D, F, G, I, J, L, M, O, P, R, and S) omCCL28-like-23 (C, D), drCCL27b-24 (F, G), lcCCL28-25 (I, J), smCCL27b-25 (L, M), trCCL28-29 (O, P), and chCCL27a-26 (R, S).
Peptide MICs determined in MHB
| Bacterial strain | MIC (μg/mL) of: | ||||||
|---|---|---|---|---|---|---|---|
| omCK11-31 | omCCL28-like-23 | drCCL27b-24 | lcCCL28-25 | smCCL27b-25 | trCCL28-29 | chCCL27a-26 | |
| Gram-negative bacteria | |||||||
| | 12.50 | 12.50 | 25.00 | 6.25 | 50.00 | 12.50 | 25.00 |
| | 25.00 | >50.00 | >50.00 | 25.00 | >50.00 | 25.00 | >50.00 |
| | >50.00 | >50.00 | >50.00 | >50.00 | >50.00 | 25.00 | >50.00 |
| | 25.00 | 25.00 | 25.00 | 12.50 | 50.00 | 25.00 | 25.00 |
| | 12.50 | 25.00 | 25.00 | 12.50 | 25.00 | 25.00 | 25.00 |
| Gram-positive bacteria | |||||||
| | 12.50 | 12.50 | 25.00 | 6.25 | 25.00 | 12.50 | 12.50 |
| | 12.50 | 12.50 | 25.00 | 6.25 | 25.00 | 12.50 | 25.00 |
| | 12.50 | 25.00 | 25.00 | 6.25 | 25.00 | 25.00 | 25.00 |
| Methicillin-resistant | 12.50 | 25.00 | 25.00 | 12.50 | >50.00 | 12.50 | 25.00 |
| Methicillin-resistant | 12.50 | 12.50 | 25.00 | 6.25 | 25.00 | 12.5 | 25.00 |
FIG 3Time-kill curves of lcCCL28-25 (4× MIC) against Gram-positive bacteria (A) and Gram-negative bacteria (B). Data are presented as mean values ± standard deviations.
FIG 4Hemolytic activities of peptides against human red blood cells (hRBCs). The absorbance value (A540) for 0% hemolysis was determined using phosphate-buffered saline (PBS) (APBS), while 100% hemolysis was established using 0.1% (vol/vol) Triton X-100 (ATriton). Percentages of hemolysis were calculated as follows: % hemolysis = [(Asample − APBS)/(ATriton − APBS)] × 100. Each measurement was performed in triplicate. Data are presented as mean values ± standard deviations.
FIG 5Cytotoxicity of lcCCL28-25 toward RAW264.7 cells (murine monocyte/macrophage cells lines) (A) and HEK293T cells (human embryonic kidney cells) (B). The MTT assay was used. PBS was used to establish the value for 100% survival. Each measurement was performed in triplicate. Data are presented as mean values ± standard deviations.
FIG 6Inhibition (A) and eradication (B) activities of lcCCL28-25 on P. aeruginosa FRD1 biofilm. The value for 0% inhibition or eradication was established without peptide. Each measurement was performed in triplicate. Data are presented as mean values ± standard deviations.
MIC values of peptides in the presence of physiological salts and mouse serum against Staphylococcus aureus USA300
| Peptide | MIC (μg/mL) in | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | 150 mM NaCl | 4.5 mM KCl | 6 μM NH4Cl | 1 mM MgCl2 | 2.5 mM CaCl2 | MS at concn (%) of: | |||
| 10 | 20 | 40 | |||||||
| lcCCL28-25 | 6.25 | 25.00 | 6.25 | 6.25 | 6.25 | 12.50 | 25.00 | 50.00 | 200.00 |
| Melittin | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 25.00 | 50.00 | 200.00 |
The control was bacteria treated with peptide only. MS, mouse serum.
FIG 7Neutropenic mouse thigh infection model. (A) Infection status of S. aureus USA300 in mouse thigh. (B) Survival plot of mice in different treatment groups. (C) Colony counts after administration of PBS, vancomycin, or lcCCL28-25 in neutropenic mouse thigh infection model. Each data point represents the value for a single mouse. All the experiments were performed in triplicate. Data are presented as mean values ± standard deviations. Data were statistically analyzed via unpaired nonparametric Mann-Whitney U test; *, P < 0.001.
FIG 8LcCCL28-25 disrupts bacterial cell membrane permeability. (A) S. aureus ATCC 25923. (B) E. coli ATCC 25922. Bacterial ingestion of SYTOX green was quantified by measuring intracellular fluorescence every 1 min. AU, absorbance units.
FIG 9Fluorescence and electron microscopy. (A, B) Fluorescence microscopy of E. coli ATCC 25922 cells (A) and S. aureus ATCC 25923 cells (B) grown without treatment or with lcCCL28-25 and stained with FM4-64, DAPI, and SYTOX green. White arrows indicate membrane-related fluorescence spots. (C, D) SEM of E. coli ATCC 25922 cells (C) and SEM and TEM of S. aureus ATCC 25923 cells (D) that were untreated or treated with lcCCL28-25. Red arrows indicate membrane deformation and detachment and also the bright areas in the cytoplasm. The electron microscopy scans were completed in duplicate, and one typical result is shown.